PRTA · CIK 0001559053 · operating
Prothena Corporation plc is a late-stage clinical biotechnology company developing monoclonal antibodies and immunotherapies targeting protein dysregulation in neurodegenerative diseases. The company's pipeline focuses on synucleinopathies, including Parkinson's disease, and tauopathies associated with Alzheimer's disease. Its lead candidate, prasinezumab, targets alpha-synuclein and is in phase 2b development for Parkinson's disease and other synucleinopathies. Additional pipeline assets include coramitug for transthyretin amyloidosis, BMS-986446 and PRX012 for Alzheimer's disease, and PRX019 for broader neurodegenerative indications, with candidates ranging from phase 1 to phase 2 clinical development.
The company operates through strategic partnerships with major pharmaceutical firms. Prothena has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. for prasinezumab and other alpha-synuclein-targeting antibodies. Additionally, the company maintains a master collaboration agreement with Bristol Myers Squibb for antibodies targeting tau and TDP-43 proteins. These partnerships provide development funding and commercialization pathways for its therapeutic candidates.
Prothena is incorporated in Ireland and headquartered in Dublin, with operations focused on the United States market. The company is publicly traded on Nasdaq with a market capitalization of approximately $0.5 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-4.53 | $-4.53 | -99.6% | |
| 2024 | $-2.27 | $-2.27 | +17.8% | |
| 2023 | $-2.76 | $-2.76 | -11.7% | |
| 2022 | $-2.47 | $-2.47 | -279.0% | |
| 2021 | $1.38 | $1.51 | +279.2% | |
| 2020 | $-0.77 | $-0.77 | -42.6% | |
| 2019 | $-0.54 | $-0.54 | +3.6% | |
| 2018 | $-0.56 | $-0.56 | +54.8% | |
| 2017 | $-1.24 | $-1.24 | +12.1% | |
| 2016 | $-1.41 | $-1.41 | -85.5% | |
| 2015 | $-0.76 | $-0.76 | -58.3% | |
| 2014 | $-0.48 | $-0.48 | — | |
| 2013 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-27 | 0001559053-26-000008 | SEC ↗ |
| 2024-12-31 | 2025-02-27 | 0001559053-25-000009 | SEC ↗ |
| 2023-12-31 | 2024-02-22 | 0001559053-24-000008 | SEC ↗ |
| 2022-12-31 | 2023-02-28 | 0001559053-23-000005 | SEC ↗ |
| 2021-12-31 | 2022-02-25 | 0001559053-22-000008 | SEC ↗ |
| 2020-12-31 | 2021-02-26 | 0001559053-21-000008 | SEC ↗ |
| 2019-12-31 | 2020-03-03 | 0001559053-20-000005 | SEC ↗ |
| 2018-12-31 | 2019-03-15 | 0001559053-19-000007 | SEC ↗ |
| 2017-12-31 | 2018-02-26 | 0001559053-18-000008 | SEC ↗ |
| 2016-12-31 | 2017-02-27 | 0001559053-17-000005 | SEC ↗ |
| 2015-12-31 | 2016-02-25 | 0001559053-16-000051 | SEC ↗ |
| 2014-12-31 | 2015-03-13 | 0001559053-15-000006 | SEC ↗ |
| 2013-12-31 | 2014-03-07 | 0001559053-14-000007 | SEC ↗ |
| 2012-12-31 | 2013-03-29 | 0001193125-13-133056 | SEC ↗ |